R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $34.64
    -0.07 (-0.20%)

    Market Cap: $25.07B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    +2.24%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.45
    Range$-0.59 - $-0.35
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-0.38+16.1%
    60d ago$-0.40+12.0%
    30d ago$-0.40+12.0%
    7d ago$-0.40+12.0%
    Current$-0.45
    Revenue Consensus
    $4M
    Range$0 - $8M
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.53 - $-0.35
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.10+75.1%
    60d ago$-0.36+11.5%
    30d ago$-0.36+11.5%
    7d ago$-0.36+11.5%
    Current$-0.41
    Revenue Consensus
    $13M
    Range$0 - $38M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.36---
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.45---
    Jun 26
    		$-0.45$-0.45+0.00%Beat-80.0%
    Mar 26
    		$-0.32$-0.35+8.57%Beat-10.3%
    Dec 25
    		$-0.24$-0.31+22.58%Beat-20.0%
    Sep 25
    		$-0.28$-0.30+6.67%Beat+6.7%
    Jun 25
    		$-0.25$-0.23-8.70%Miss-38.9%
    Mar 25
    		$-0.29$-0.26-10.31%Miss-52.6%
    Dec 24
    		$-0.20$-0.24+16.67%Beat+4.8%
    Sep 24
    		$-0.30$-0.24-25.00%Miss-3.4%
    Jun 24
    		$-0.18$-0.24+25.00%Beat+35.7%
    Mar 24
    		$-0.19$-0.30+36.67%Beat+5.0%
    Dec 23
    		$-0.21$-0.27+22.22%Beat+50.0%
    Sep 23
    		$-0.29$-0.27-7.41%Miss+9.4%
    Jun 23
    		$-0.28$-0.28+0.00%Beat+6.7%
    Mar 23
    		$-0.20$-0.36+44.44%Beat+25.9%
    Dec 22
    		$-0.42$-0.32-31.25%Miss-2.4%
    Sep 22
    		$-0.32$-0.34+5.88%Beat+0.0%
    Jun 22
    		$-0.30$-0.28-7.14%Miss-7.1%
    Mar 22
    		$-0.27$-0.32+15.63%Beat-173.0%
    Dec 21
    		$-0.41$-0.24-70.83%Miss-4000.0%
    Sep 21
    		$-0.32$-0.36+11.11%Beat-
    Jun 21
    		$-0.28$-0.26-7.69%Miss-1754.3%
    Mar 21
    		$0.37N/AN/ABeat+245.4%
    Dec 20
    		$-0.01N/AN/ABeat-
    Sep 20
    		$0.00$0.00N/ABeat-
    Mar 20
    		$-0.02$0.00N/AMiss-
    Dec 19
    		$-0.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-26.85EV/EBITDA0.74x
    Price/FCF-30.05xFCF Yield-3.33%
    Profitability
    Profit Margin0.00%Operating Margin-25408.00%
    ROE-8.52%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio16.72xQuick Ratio16.72x
    Trading Statistics
    Beta1.13Avg Volume7.57M
    52-Week High$37.9752-Week Low$11.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$36.44
    SMA 20$36.05
    SMA 50$35.15
    SMA 200$28.21
    EMA 10$35.99
    EMA 20$35.86
    EMA 50$34.65
    EMA 200$28.47

    MACD

    Line: 0.34Signal: 0.59Hist: -0.24

    ADX

    ADX: 14.6+DI: 21.3-DI: 26.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$37.90

    Bollinger Bands

    Upper Band$37.95
    Lower Band$34.15
    %B Position1054%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    43.9

    Momentum Oscillators

    Stoch %K36.3
    Stoch %D54.2
    Williams %R-84.2
    ROC (10d)-4.4%
    Momentum-1.60
    CCI (20d)-126.3
    MFI (14d)36.7

    Volatility Measures

    ATR (14d)$1.27(3.7%)
    StdDev (20d)0.95
    Hist Vol39.5%(Moderate)

    Volume Flow

    VWAP$34.66
    OBV310.8M
    AD Line181.0M
    CMF (20d)0.004

    Volume Metrics

    Avg Vol (20d)7.6M
    Vol Ratio5.1x(High)
    VWMA (20d)$35.68

    Pivot Points

    R3$38.78
    R2$37.95
    R1$36.33
    Pivot Point$35.51
    S1$33.89
    S2$33.06
    S3$31.44

    Advanced Oscillators

    TSI8.93
    Ultimate Osc39.6
    KST45.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.44M$2.52M$2.00M$1.57M$2.17M$7.57M$9.02M$4.47M$7.99M$-8,121,000$15.56M$3.65M
    Cost of Revenue$0$-154,000$0$0$0$-213,000$0$0$213,000$4.41M$0$0
    Gross Profit$1.44M$2.67M$2.00M$1.57M$2.17M$7.78M$9.02M$4.47M$7.78M$-8,121,000$15.56M$3.65M
    Operating Expenses$367.44M$-412,566,000$341.15M$307.80M$287.09M$292.75M$283.40M$346.19M$110.01M$132.00M$-5,111,893,000$217.54M
    R&D$202.02M$198.94M$165.38M$164.57M$152.92M$145.24M$141.59M$143.07M$120.51M$91.84M$108.15M$128.74M
    SG&A$165.53M$158.25M$175.07M$143.13M$134.02M$147.09M$141.54M$202.88M$99.89M$43.20M$128.17M$88.58M
    Operating Income$-365,993,000$415.24M$-339,153,000$-306,233,000$-284,922,000$-284,965,000$-274,381,000$-341,713,000$-102,235,000$-140,119,000$5.13B$-213,891,000
    Interest Income$73.56M$26.29M$64.86M$173.84M$29.20M$70.63M$40.54M$118.15M$87.35M$114.78M$21.49M$-14,196,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$27.52M
    Income Before Tax$-294,564,000$454.10M$-290,369,000$-159,044,000$-269,262,000$-203,054,000$-234,513,000$-224,383,000$-19,640,000$-18,190,000$5.15B$-241,406,000
    Income Tax Expense$-3,958,000$98.35M$23.33M$7.00M$4.65M$49.32M$-25,568,000$12.46M$11.96M$-5,850,000$22.36M$3.24M
    Net Income$-290,606,000$355.74M$-313,701,000$-166,039,000$-273,911,000$-252,375,000$118.08M$-279,924,000$57.49M$-182,496,000$5.07B$-331,118,000
    EBITDA$-373,214,000$421.54M$-363,259,000$-341,787,000$-308,422,000$-287,915,000$-301,397,000$-362,725,000$-102,110,000$-136,660,000$5.14B$-221,623,000
    EBIT$-368,123,000$427.81M$-355,227,000$-332,886,000$-298,459,000$-273,685,000$-275,050,000$-342,531,000$-106,993,000$-141,885,000$5.13B$-227,210,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ROIV

    News

    Cantor Fitzgerald reiterates Roivant Sciences stock Overweight rating

    Cantor Fitzgerald has reiterated its Overweight rating on Roivant Sciences (NASDAQ:ROIV) after updating its model following the first-quarter earnings. Despite the stock trading above its fair value according to InvestingPro, analysts anticipate significant sales growth, with revenue expected to nearly quadruple by fiscal year 2027. TD Cowen also raised its price target for Roivant to $50 from $41, maintaining a Buy rating and highlighting potential catalysts in the second half of the year.

    Investing.com•8/25/26•
    Bullish

    Roivant (NASDAQ: ROIV) president settles RSU taxes in shares

    Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), had 13,909 common shares withheld on August 20, 2026, to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs). This transaction, valued at $36.84 per share, was a "net settlement" and not an open-market sale. Following this, Venker directly holds 1,599,154 common shares.

    Stock Titan•8/25/26•
    Neutral

    Roivant (NASDAQ: ROIV) CFO uses shares to cover RSU taxes

    Roivant Sciences Ltd. (ROIV) CFO Richard Pulik had 5,749 Common Shares withheld on August 20, 2026, to cover tax obligations from the vesting of previously granted RSUs. This "net settlement" transaction was valued at $36.84 per share, totaling approximately $212,000. Following this, Pulik directly holds 271,810 Common Shares, which include shares acquired through the company’s Employee Stock Purchase Plan.

    Stock Titan•8/25/26•
    Neutral

    Roivant Sciences Insider Sold Shares Worth $12,360,813, According to a Recent SEC Filing

    An insider at Roivant Sciences Ltd. (ROIV) sold shares valued at $12,360,813, as disclosed in a recent SEC filing. This transaction follows another significant insider sale of $24,160,402 on August 19, 2026. The company is a biopharmaceutical firm focused on accelerating the development of medicines, with a pipeline including treatments for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and pulmonary hypertension.

    www.marketscreener.com•8/24/26•
    Somewhat-Bearish

    Roivant Sciences(ROIV.US) Officer Sells US$12.36 Million in Common Stock

    An officer at Roivant Sciences (ROIV.US) has sold 1.32 million shares of common stock for a total of US$12.36 million. The transaction was disclosed in a Form 4 filing with the SEC.

    Moomoo•8/22/26•
    Bearish

    Frequently Asked Questions About ROIV

    Does ROIV pay dividends?
    Roivant Sciences Ltd (ROIV) does not currently pay a regular dividend.
    What is ROIV's market cap?
    Roivant Sciences Ltd (ROIV) has a market capitalization of $25.07B with a current stock price of $34.64.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In